Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.56 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | KRAS | P01116 | 8/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.54 |
| ▸ | HINT1 | P49773 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180928 | 1.00 | NT5E (0.61) | NT5ETGM2IMPDH2FUT5KRAS | |
| SCHEMBL8669732 | 0.93 | NT5E (0.59) | NT5ETGM2IMPDH2FUT5KRAS | |
| SCHEMBL1269745 | 0.92 | NT5E (0.61) | NT5ETGM2IMPDH2FUT5KRAS | |
| SCHEMBL6027526 | 0.89 | NT5E (0.61) | NT5ETGM2IMPDH2FUT5KRAS | |
| SCHEMBL1697432 | 0.89 | NT5E (0.61) | NT5ETGM2IMPDH2FUT5KRAS | |
| L-Fucose SCHEMBL18992533 | 0.89 | TGM2 (0.67) | NT5ETGM2IMPDH2FUT5KRAS | |
| L-Fucose SCHEMBL20607674 | 0.89 | TGM2 (0.67) | NT5ETGM2IMPDH2FUT5KRAS | |
| Glucuronic Acid SCHEMBL6046180 | 0.87 | TGM2 (0.66) | NT5ETGM2IMPDH2FUT5KRAS | |
| Glucuronic Acid SCHEMBL27957333 | 0.87 | TGM2 (0.66) | NT5ETGM2IMPDH2FUT5KRAS | |
| Glucuronic Acid SCHEMBL5941537 | 0.87 | TGM2 (0.66) | NT5ETGM2IMPDH2FUT5KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981541-A1 | SYNTHESIS AND USE OF ISOTOPICALLY-LABELLED GLYCANS | Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE (ES) | 2016-02-10 | — | — | EP | disclosed |
| WO-2014161960-A1 | SYNTHESIS AND USE OF ISOTOPICALLY-LABELLED GLYCANS | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOMATERIALES (ES) | 2014-10-09 | — | — | WO | disclosed |
| US-8716557-B2 | Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2014-05-06 | — | — | US | disclosed |
| EP-1974040-B1 | Compositions and methods for humanization and optimization of N-glycans in plants | BIOLEX THERAPEUTICS INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20110144308-A1 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS | BIOLEX THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7884264-B2 | Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants | BIOLEX THERAPEUTICS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090060921-A1 | GLYCAN-OPTIMIZED ANTI-CD20 ANTIBODIES | BIOLEX THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1973940-A2 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS | Biolex Therapeutics, Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1974040-A2 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS | Biolex Therapeutics, Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080066200-A1 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS | BIOLEX, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007084926-A2 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS | BIOLEX THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084922-A2 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS | BIOLEX THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2005017115-A2 | CORD BLOOD-DERIVED HEMATOPOIETIC PROGENITOR CELLS | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2005-02-24 | — | — | WO | disclosed |
| US-6528274-B1 | Sialyltransferase is used to transfer an analogue of sialic acid to the non-reducing sugar terminus having a fucosyl group | SYNSORB BIOTECH, INC. (CA) | 2003-03-04 | — | — | US | disclosed |
| EP-1108054-A1 | METHOD FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | SYNSORB Biotech Inc. (CA) | 2001-06-20 | — | — | EP | disclosed |
| US-6194178-B1 | ALPHA-2,3-SIALYLTRANSFERASE IS USED TO TRANSFER CMP-SIALIC ACID, TO THE NON-REDUCING SUGAR TERMINUS OF AN OLIGOSACCHARIDE HAVING A FUCOSYL GROUP IN THE PENULTIMATE SACCHARIDE UNIT TO THE NON-REDUCING SUGAR TERMINUS | SYNSORB BIOTECH INC. (CA) | 2001-02-27 | — | — | US | disclosed |
| WO-2000014264-A1 | METHOD FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | SYNSORB BIOTECH, INC. (CA) | 2000-03-16 | — | — | WO | disclosed |
| EP-0589933-B1 | METHODS FOR THE ENZYMATIC SYNTHESIS OF ALPHA-SIALYLATED OLIGOSACCHARIDE GLYCOSIDES | GLYCOMED INC (US) | 1997-02-12 | — | — | EP | disclosed |
| EP-0589933-A1 | METHODS FOR THE ENZYMATIC SYNTHESIS OF ALPHA-SIALYLATED OLIGOSACCHARIDE GLYCOSIDES. | ALBERTA RES COUNCIL (CA) | 1994-04-06 | — | — | EP | disclosed |
| WO-1992022661-A1 | METHODS FOR THE ENZYMATIC SYNTHESIS OF ALPHA-SIALYLATED OLIGOSACCHARIDE GLYCOSIDES | ALBERTA RESEARCH COUNCIL (CA) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060921-A1 | GLYCAN-OPTIMIZED ANTI-CD20 ANTIBODIES | FUT4, FUT6, FUT8 | NT5E 1019/4885TGM2 1193/4885IMPDH2 2069/4885 |
| US-20110144308-A1 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS | FUCA2, FUCA1, B4GALT1 | NT5E 722/4885TGM2 659/4885IMPDH2 3285/4885 |
| US-20080066200-A1 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS | FUCA2, FUCA1, B4GALT1 | NT5E 722/4885TGM2 659/4885IMPDH2 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.